From Reactive to Protective
Achieving Broad Multilineage Myelosuppression Prevention in Extensive-Stage
Small Cell Lung Cancer
This Learning Center is designed for multidisciplinary clinicians involved in the prevention, recognition, and management of chemotherapy-induced myelosuppression (CIM) in individuals with extensive-stage small cell lung cancer (ES-SCLC). Through this two-part activity, our goal is to equip oncology teams with the knowledge and practical tools needed to navigate CIM prevention/management strategies and effectively integrate them into clinical practice.
Activities
Managing Myelosuppression in ES-SCLC: From Reactive to Proactive with CDK4/6 Inhibition
Credit Available
ICPE: 0.5 Interprofessional Continuing Education (IPCE) credit
Physician: AMA PRA Category 0.5 Credit(s)™
Nursing: 0.5 ANCC contact hours
Pharmacy: 0.5 ACPE contact hours
Activity Description
Multiple therapeutic strategies are available to help mitigate chemotherapy-induced myelosuppression (CIM) in extensive-stage small cell lung cancer (ES-SCLC). However, conventional strategies to prevent and manage chemotherapy-induced cytopenias—including granulocyte colony-stimulating factor (G-CSF), red blood cell and platelet transfusions, and erythropoiesis-stimulating agents—present with important clinical limitations. Prophylactic cyclin-dependent kinase 4/6 (CDK4/6) inhibitors offer a proactive approach to multilineage myeloprotection aimed at reducing the multisystemic consequences of CIM. As the evidence supporting CDK4/6 inhibitors expands, it is increasingly important for clinicians to understand their role in ES-SCLC management. Join expert faculty as they review the current treatment landscape for CIM and examine the clinical evidence supporting CDK4/6 inhibitors for myeloprotection in ES-SCLC.
Activity Faculty
Course Director: Ralph V. Boccia, MD, FACP
Course Faculty: Amber Broussard, PharmD and Victoria Sherry, DNP, ANP-BC, AOCNP
Implementing Multidisciplinary Myelosuppression Prevention Strategies in ES-SCLC Supportive Care
Credit Available
ICPE: 0.5 Interprofessional Continuing Education (IPCE) credit
Physician: AMA PRA Category 0.5 Credit(s)™
Nursing: 0.5 ANCC contact hours
Pharmacy: 0.5 ACPE contact hours
Activity Description
Effective management of chemotherapy-induced myelosuppression (CIM) in extensive-stage small cell lung cancer (ES-SCLC) requires coordinated, multidisciplinary collaboration among physicians, advanced practice providers, nurses, and clinical pharmacists. However, gaps in role delineation, workflow integration, and team-based planning may delay the timely implementation of evidence-based supportive care strategies, including prophylactic cyclin-dependent kinase 4/6 (CDK4/6) inhibitors for multilineage myeloprotection. Join an interdisciplinary expert faculty as they discuss practical approaches to integrating CIM prevention and management strategies into multidisciplinary workflows, with a focus on optimizing care coordination, communication, and implementation in clinical practice.
Activity Faculty
Course Director: Ralph V. Boccia, MD, FACP
Course Faculty: Amber Broussard, PharmD and Victoria Sherry, DNP, ANP-BC, AOCNP